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Abstract
Understanding the phenotypic drug response on cancer cell lines plays a vital
rule in anti-cancer drug discovery and re-purposing. The Genomics of Drug Sensi-
tivity in Cancer (GDSC) database provides open data for researchers in phenotypic
screening to test their models and methods. Previously, most research in these ar-
eas starts from the fingerprints or features of drugs, instead of their structures. In
this paper, we introduce a model for phenotypic screening, which is called twin
Convolutional Neural Network for drugs in SMILES format (tCNNS). tCNNS is
comprised of CNN input channels for drugs in SMILES format and cancer cell
lines respectively. Our model achieves 0.84 for the coefficient of determinant(R2)
and 0.92 for Pearson correlation(Rp), which are significantly better than previ-
ous works[3, 16, 30]. Besides these statistical metrics, tCNNS also provides some
insights into phenotypic screening.
1 Introduction
Historically, drug discovery was phenotypic by nature. Small organic molecules ex-
hibiting observable phenotypic activity (e.g. whole-cell activity) were detected, with
a famous example being penicillin, which was serendipitously found. Phenotypic
screening, an original drug screening paradigm, is now gaining new attention given the
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fact that in recent years the number of approved drugs discovered through phenotypic
screens has exceeded those discovered throughmolecular target-based approaches. The
latter, despite being the main drug discovery paradigm in the past 25 years, can poten-
tially suffer from the failure in identifying and validating the therapeutic targets. In
reality, most FDA approvals of first-in-class drugs actually originated from phenotypic
screening before their precise mechanisms of actions or molecular targets ware elab-
orated. A popular example of this is aspirin (acetylsalicylic acid), for which it took
nearly a century to elucidate the mechanism of its actions and molecular targets.
There are some public phenotypic screening datasets online to support the study
the pharmacologic functions of drugs. Cancer Cell Line Encyclopedia (CCLE) and
Genomics of Drug Sensitivity in Cancer (GDSC) are the most popular datasets in the
field[4].
A pioneer work using machine-learning approaches to predict drug response on
cancer cell lines was by Menden et al. [30]. The authors used a neural network to
analyze the response of drugs to cancer cell lines on the GDSC dataset. Their main
result was the achievement of 0.72 for the coefficient of determination and 0.85 for
Pearson correlation. [3] and [16] are other two works on GDSC dataset. The first used
kernelized Bayesian matrix factorization to conduct QSAR analysis on cancer cell lines
and anti-cancer drugs, and the second used multivariate random forests. Both of their
results are not as good as those in [30], which is chosen to be the benchmark for our
work.
The first wave of applications of deep learning in pharmaceutical research has
emerged in recent years. Its utility has gone beyond bioactivity predictions and has
shown promise in addressing diverse problems in drug discovery. Examples cover
bioactivity prediction[31], de novo molecular design[11], synthesis prediction[29] and
biological image analysis[5, 26]. A typical example of applying deep learning in
protein-ligand interaction is the investigation done by Ragoza et al[35].
Convolutional neural network (CNN) is a model in machine learning which can
detect the patterns in data and support classification and regression[44]. CNN has
achieved breaking-through results in many areas including pharmaceutical research
[18, 40, 32] and has won the championship in ImageNet-2012[24].
Inspired by the achievements of CNN in these areas, we are interested to see if
CNN, compared to conventional machine-learning techniques[30, 3, 16], could signif-
icantly improve the prediction accuracy of phenotypic drug response on cancer cell
lines. CNN has not been applied to this problem. This is the first study in exploiting
deep convolutional neural networks in predicting phenotypic anti-cancer drug response.
In this paper, we introduce a twin CNN networksmodel applied to drugs in SMILES
format as input, and we call this model tCNNS. tCNNS comprises a CNN network for
drugs and another CNN network for cancer cell lines, which will be explained in de-
tail later. Comparing to previous work, we use the latest version of the GDSC dataset,
which is bigger and more complete, and our model is more advanced. Most impor-
tantly, we achieve much better results than previous works. We share our model online,
hoping to make a contribution to other researchers.
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2 Relate Work
Recently, in drug discovery, researchers start to use the molecular structure of drugs
directly as features [14, 13, 15, 2] instead of using extracted features from open source
softwares[6, 38]. Due to their good ability to process high-dimensional structure on
data, deep learning has been largely adopted in this area[25, 37, 9].
In [9], the author stated that both the qualitative classifiers and the quantitative
structure-activity relationship (QSAR) models in this area depend on the molecular de-
scriptor, which is the decisive step in the model development process. In the recent
two years, there are several different deep neural network models that are trained di-
rectly from drugs structure and avoiding the decisive step. Those deep neural network
models include unsupervised auto-encoder (AE), and supervised convolution neural
network(CNN), recurrent neural network (RNN).
[14] and [20] converted simplifiedmolecular input line entry specification (SMILES)
of drug into vectors using unsupervised auto-encoder. Those vectors can be used as
features or fingerprint of drugs. [2] and [41] further extended this method for drug
discovery. They predicted the use of drugs by comparing the similarity between those
vectors of drugs.
One of the direct ways to apply CNN on drug structures is to apply CNN on the
image of drugs[12], instead of the formulas of drugs. In [12], the author adopts a
computer vision method to screen the image of drugs. The advantage of starting from
the image of drugs instead of the formulas of drugs is that it can avoid the massive work
of handling the diversity of drugs. However, the disadvantages are that the accuracy is
compromised because the information will be distorted when mapping drugs structures
to images and the performance of this method relies on the quality of image processing.
Beside applying CNN on drug images, it is also possible to apply CNN on molec-
ular 3D structures directly[39]. In this paper, the author predicted the binding energy
of the small area around an atom, instead of the entire structure of drugs. We think
that it will be interesting to compare the different representations of drugs, such as
the 3D structured, the feature vectors learned from SMILES and the features extracted
from other software like PaDEL [43]. They may have different influences on different
problems. However, we did not find any kind of such comparisons.
Even though RNN is usually used to handle time sequence data[42] instead of
spatial data, it is very impressive that [27] applied RNN onmolecule SMILES to predict
its solubility. They first converted the SMILES into indirect graphs, and then fed it
into an RNN. In this work, they only considered the property of drugs alone, without
considering the interactions among drugs and other biological factors, such as cell lines
or proteins.
The benchmark work we used to compare with our model is [30], where the author
used a neural network to analyze the IC50 of drugs to cancer cells on the same dataset
as ours. We think their network structure is not advanced enough, and the features
they used are not informative enough. We design our tCNNS, a convolution neural
network (CNN) based model, to predict the interaction between drugs and cell lines,
and it performs better in the experiments.
3
3 Methods
In this section, we will introduce the chosen database GDSC with preprocessing steps
and the adopted neural network structure in details to make our experiments easier to
replicate.
3.1 Data Acquisition and Preprocessing
Genomics of Drugs Sensitivity in Cancer (GDSC) [8] is a public online database about
the relationship among many types of cancer and various anti-cancer drugs. Cancer
cell lines in GDSC are described by their genetic features, such as mutations state and
copy number variances. For the drugs, GDSC provides their names and the compound
id (CID). In chemistry, CID is a unique number assigned to each molecular and can be
used as the reference number to extract more information about the drugs such as their
molecular structures from other databases. GDSC uses IC50 as the metric of drugs’
effect on cancers, which means how much of the drugs is needed to inhibit cancer by
half. The less the value, the more effective the drug is. GDSC is an ongoing project
and is being updated regularly. In this paper, we use version 6.0 of GDSC, and the
benchmark of our paper [30] used version 2.0 of the GDSC.
We downloaded three files from GDSC:
(a) Drug list.csv, which is a list of 265 drugs. Each drug can be referred by its CID
or name.
(b) PANCANCER Genetic feature.csv, which is a list of 990 cancer cell lines from
23 different types of cancers. Each cell line is described by at most 735 features.
Any feature belongs to one of the two categories: mutation state or copy number
alteration.
(c) PANCANCER IC.csv, which contains the IC50 information between 250 drugs
and 1074 cell lines.
Note that the numbers of drugs in the file (a) and the file (c) are inconsistent, and
the numbers of cell lines in the file (b) and the file (c) are also inconsistent. Some cell
lines have less than 735 features. Besides, GDSC does not provide the features for
drugs, which have to be downloaded from other datasets. All of these indicate that a
preprocessing is needed to clean the data.
The first step is to purify the drug list. There are 15 repeating items in the file
(a) which are removed. Some CIDs in the file (a) are inconsistent with the CIDs that
in PubChem [23], which is a popular public chemical compounds database. To keep
the consistency, we use the CIDs from PubChem. Some drugs cannot be found in
PubChem by referring their names in the file (a) and they are removed. In the end, 223
drugs with both names and CIDs are left.
The second step is to purify the cell lines list. For the 990 cell lines in the file (b),
42 of them has less than 735 features. We remove these cell lines and there are 948 cell
lines left.
In the third step, we only keep the IC50 values between the remaining drugs after
the first step and the remaining cell lines after the second steps. All the other IC50
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values in the file (c) are removed. In summary, there are 223 drugs and 948 cell lines
after the preprocessing. Amon the g 223 × 948 = 211, 404 interacting pairs, 81.4%
(172, 114) of the IC50 values are provided in file (c), and 18.6% (39, 290) of the IC50
are missing.
The IC50 data in file (c) are the logarithm of their real value. To make it easy for
training and comparison, we follow the method in [30] to normalize the logarithmic
IC50 values into the (0, 1) interval. Given a logarithmic IC50 value x, we first take
exponential of it to get the real value y = ex and then use the following function to
normalize y:
y 7→
1
1 + y−0.1
.
Usually y is very small (< 10−3), and the parameter −0.1 is chosen to distribute the
result more uniformly on the interval (0, 1) [30].
3.2 Numerical Descriptor Extraction
Recently, there are some pioneering works that apply deep neural network (DNN) di-
rectly on the simplifiedmolecular-input line-entry system (SMILES) of drugs. SMILES
is a linear notation form to represent the structure of molecules, in which letters, digits
and special characters are used to represent the chemical elements in a molecule. For
example, ”C” is for carbon atom, ”=” is for covalent bond between two atoms, Carbon
dioxide can be represent as O=C=O, and aspirin can be represented as O=C(C)OC1CCCCC1C(=O)O.
There are some challenges to apply convolution neural network (CNN) on drugs
in SMILES format: first, SMILES can be constructed in various ways and there can
be many possible SMILESs for each drug; second, the size of the samples for a CNN
should be consistent, but the lengths the SMILES format of drugs are different from
each other; third, and more importantly, the SMILES format is composed of different
letters representing different chemical elements, such as atoms and bonds, and it does
not make sense to apply convolution operation among different chemical elements. To
solve these problems, preprocessing is needed to convert the SMILES into a uniform
format, and restrict convolutional operation among the same chemical elements.
To keep unique SMILES format for the drugs, we use the canonical SMILES[34]
for the drugs. Among 223 drugs, the canonical SMILES of 184 of them can be found
from PubChemPy by the drugs names, which is a python interface for PubChem. The
canonical SMILES of the remaining 39 drugs are downloaded from the Library of the
Integrated Network-based Cellular Signatures (LINCS) [21] instead.
The longest SMILES for the drugs contains 188 symbols, andmost SMILES lengths
are between 20 and 90. To keep the size consistent and retain the complete information,
all the SMILESs are left aligned with space padding in the right if they are shorter than
188.
The neural network cannot directly take the drugs in SMILES format as input, and
we need to convert the SMILES format (they are uniform length now after handling
the second challenge) into a format that can be used in the neural network. There are
72 different symbols in the SMILES format for the total 223 drugs. The distribution of
these symbols is quite imbalanced. For example, carbon atom [C] appears in all the
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223 drugs, but both the gold atom [Au] and chlorine atom [Cl] appear only once.
Suppose we use rows to represent different symbols, and use columns to represent
positions in the SMILES format, then each drug in SMILES format can be converted
into a 72 ∗ 188 one-hot matrix which only contains 0 and 1. The row number 72
represents 72 possible symbols, and column number 188 represents the longest length
of SMILES. In the one-hot matrix for a drug, a value 1 at row i and column j means
that the ith symbol appears at jth position in the SMILES format for the drug. In our
model, the column of the one-hot matrix is treated as different channels in CNN, and
the 1D convolutional operation will be applied along each row of the one-hot matrix,
which restricts convolutional operation within the same chemical element.
3.3 Deep Neural Network
Figure 1: The upper part is the branch for drugs, and the lower part is the branch for cell lines.
Both of them are connected to a fully connected network in the right. The general work-flow
of our model is from left to right. The left is the input data of one-hot representations for drugs
and the feature vectors for cell lines. The black square stands for 1 and empty square stands for
0. In the middle is the two convolution neural networks for drugs and cell lines. They take the
one-hot representations and feature vectors as input data respectively, and their outputs can be
interpreted as the abstract features for drugs and cell lines. The structures of the two convolution
neural networks are similar. The right is a fully connected network that does regression analysis
from the IC50 to the abstract features from the two CNNs in the middle part.
The structure of our model is shown in Figure 1. The input data for our model is the
one-hot representation of drugs (phenanthroline is used as an example for the drugs)
and the feature vectors of the cell lines. The work-flow can be divided into two stages
as follows.
During the first stage, we build a model with two convolutional neural networks
(CNN) branches to distill features for drugs and cell lines separately. We use 1D CNN
for the cell-line branch since the input data is 1D feature vectors for cell lines. We
also use 1D CNN for the drug branch and treat different symbols as different channels
in CNN. The convolution is applied along the length of the SMILES format. The
structures for the two branches are the same. For each branch, we use three similar
layers: each layer with convolution width 7, convolution stride 1, max pooling width
3, and pooling stride 3. The only difference among the layers is that their number of
channels is 40, 80 and 60, respectively. The choices of those parameters for the CNN
are inspired by the model in [22], in which the author chose a three-layers network
model and used a prime number as the filter width. We find that either reducing the
pooling size or adding the channel number has the potential to enhance our model but
with the cost of losing stability. Losing stability means that the experiments results
sometimes become un-repeatable and it will be explained in detail in Section 4.
In the second stage, after the two branches of CNN, there is a fully connected
network (FCN), which aims to do the regression analysis between the output of the
two branches and the IC50 values. There are three hidden layers in the FCN, each with
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1024 neurons. We set the dropout probability to be 0.5 for the FCN during the training
phase [22].
We implemented our model on TensorFlow v1.4.0 [1], which is a popular DNN li-
brary with many successful applications [36, 1]. The data and code of this paper can be
downloaded fromhttps://github.com/Lowpassfilter/tCNNS-Project.
3.4 Performance Measures
We adopt the metrics of the coefficient of determination (R2), Pearson correlation co-
efficient (Rp), and root mean square error (RMSE) to measure the performance of our
model, as in the benchmark paper [30].
R2 measures variance proportion of the dependent variables that is predictable from
the independent variables. Let yi be the label of a sample xi, and our label prediction
on xi is fi. The error of our prediction, or residual, is defined as ei = yi − fi. Let the
mean of yi be y¯ =
1
n
∑
i yi, We have total sum of squares:
SStot =
∑
i
(yi − y¯)
2
regression sum of squares:
SSreg =
∑
i
(fi − y¯)
2
residual sum of squares:
SSres =
∑
i
(yi − fi)
2 =
∑
i
e2i
R2 is defined as:
R2 = 1−
SSres
SStot
.
Rp measures the linear correlation between two variables. We use Y as the true
label and F as the corresponding prediction for any sample. Let the mean and standard
deviation of Y be Y¯ and σY respectively, and those for the prediction F be F¯ and σF
respectively. Rp is defined as:
Rp =
E[(Y − Y¯ )(F − F¯ )]
σY σF
.
RMSE measures the difference between two variables Y and F , and RMSE is
defined as:
RMSE =
√
E[(Y − F )2] .
4 Results and Discussion
In this section, we demonstrate the performance of our algorithm tCNNS with vari-
ous data input settings, and it achieves high scores in the circumstances we set in the
experiments.
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4.1 Rediscovering Known Drug-Cell Line Responses
In the 223× 948 drug-cell line interaction pairs, GDSC provides the IC50 for 172, 114
of them. In this part, we split those known pairs into 80% as the training set, 10% as
the validation set, and 10% as the testing set. In each epoch, parameters in tCNNS are
updated using gradient descent on the training set. The validation set is used to check
the performance of the tCNNS. If the RMSE on the validation set does not decrease
in 10 recent epochs, the training process stops and the predictions of our model on the
testing set are compared with the given IC50 values in GDSC.
The experiments are set in this way to stimulate the real situations in which we
want to train a model on data with labels and apply the model on data without labels.
The validation set is separated from the training set so that we can choose a suitable
time to stop training independent and avoid the problem of over-fitting.
We check the regression accuracy of our model by comparing our predictions
against the IC50 provided in GDSC, and the results are displayed in Figure 2.
Figure 2: Regression results on testing set compared to the ground truth IC50 values. The x
axis is the experimental IC50 in natural logarithmic scale, and the y axis is the predicted IC50
in natural logarithmic scale. Different colors demonstrate how many testing samples fall in each
small square of 0.1 × 0.1, or the hot map of the distribution, where dark purple indicates more
samples (around 30 samples per small square 0.1 × 0.1) and light blue indicates fewer samples
(less than 5 samples per small square 0.1× 0.1)
In the experiments, our model tCNNS outperforms previous work [30] in many
ways: The efficiency of determination (R2) is increased from 0.72 to 0.84, the Pear-
son correlation(Rp) is increased from 0.85 to 0.92, and the root mean squared error
(RMSE) is reduced from 0.83 to 0.027.
Many hyper-parameters affect the performance of our model tCNNS, such as the
number of layers and filter size. After examining, we find that smaller pooling size and
more numbers of channels can enhance the performance furthermore but decrease the
stability. Take the pooling size for example. When the it is reduced from 3 to 2, R2
is further increased from 0.84 to 0.92 and Rp is further increased from 0.93 to 0.96.
The cost of this enhancement is that the network becomes unstable and diverge [19]
during the training. To keep the experiments results repeatable, we report the results
with parameters that ensure our experiments stable
In Figure 2, we notice that tCNNS is most accurate in the middle part, but less
accurate in the two ends in the figure. Its outputs are not small enough when the
experimental IC50 values are very small and are not big enough when the data are huge.
This means that tCNNS can be further optimized if we can enhance its performance in
the two ends.
In the experiment, we do not recover the performance reported in [30] using the
network structure in it. After replacing its networkwith tCNNS,We find that tCNNS do
not converge using the features extracted from PaDEL. Finally, we replace the network
in [30] with a deeper one, a network with three hidden layers and 1024 neurons in
each hidden layer. This modified benchmark gets the R2 around 0.65 and Rp around
0.81, which is shown on supplementary Figure 1. From this figure, we can see that
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the result is clearly horizontally stratified, which means that the neural network lacks
representation power using PaDEL features.
Based on these results, we conclude that the connections among the IC50 values
and the SMILES format of drugs are stronger than that among the IC50 values and
features extracted using PaDEL.
4.2 Predicting Unknown Drug-Cell Line Responses
Previously, we split the known drug-cell line interaction pairs into training, validation,
and testing set to check the accuracy of tCNNS. In this part, we predict the values for
those missing pairs by training tCNNS on the known items. The known pairs are split
into 90% as the training set, and 10% as the validation set. Again, if the RMSE on the
validation set does not decrease in 10 recent epochs, the training process stops and the
trained network will be used to predict the values for the missing items. The results are
shown in Figure 3.
Figure 3: The predicted missing IC50 values. We range the drugs according to the median of
their predicted IC50 values with cells. The horizontal axis is the drug names, and the vertical
axis is their negative log10(IC50) values with cells. The left part is the top 20 drugs with lowest
IC50 median, which means that they are probably the most effective drugs, and the right part is
the last 20 drugs with the highest IC50 median, which means that they are the most ineffective
drugs. The numbers in each column are the number of missing IC50 values for each drug in the
dataset, which can indicate the confidence level of the distribution.
Figure 3 is the box plot of the predicted IC50 values for missing items grouped by
drugs. For each drug, the box represents the distribution of the values with its related
cell lines. The drugs are sorted by the median of the distribution: the 20 drugs with
highest median and 20 drugs with the lowest median value are plotted. Since we do not
know the real value for these missing pairs, the accuracy of our prediction is stated by
survey and analysis as follows.
Bortezomib is the best drug in our prediction. In fact, the top 40 pairs with the
lowest IC50 value are all from Bortezomib with some other cell lines. The outstanding
performance of Bortesomib in missing pairs is consistent with that in the existing pairs.
There is some supporting information in [7] that the author found that Bortezomib can
sensitize cell lines to many other anti-cancer drugs.
Aica ribonucleotide and Phenformin have the poorest performance in our predic-
tion. Based on our survey, the former one is initially invented to prevent blood flow,
and the later one is initially used as an anti-diabetic drug. These two drugs have the po-
tential to cure cancer because they can inhibit the growth of cell (Aica ribonucleotide)
or inhibit the growth of Complex I (Phenformin), but their effects are limited since
anti-cancer is only the side effect of these them, not their main function.
Based on our predictions, the IC50 of drug Bortezomib with cell line NCI-H2342
is 1.19 ∗ 10−4µg. This is the third smallest in our predictions and it indicates a good
therapeutic effect. This prediction is supported by the findings in [10][17] that Borte-
zomib is able to control Phosphorylation that causes lung cancer and NCI-H2342 is a
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lung cell line. Similar evidence to supporting this prediction can also be found in Cell
Signaling Technology’s 2011 published curation set. 1
4.3 Retraining Without Extrapolated Activity Data
For each drug in GDSC, there are two important thresholds called minimum screening
concentration (min conc), which is the minimum IC50 value verified by biological ex-
periments, and maximum screening concentration (max conc), which is the maximum
IC50 value verified by biological experiments. Any IC50 beyond these two thresholds is
extrapolated, and not verified by experiments. In general, IC50 value within min conc
and max conc is more accurate than those outside of the thresholds.
In the GDSC data that we use, only max conc is provided, and there are 64, 440
IC50 values below max conc, which is about 37% in the whole existing 172, 114 IC50
values.
In this part, tCNNS is trained on the IC50 values below the max conc threshold.
We keep 10% data for validating and 10% data for testing and reduce the percentage of
data used for training from 80% to 1%. The regression result is shown in supplementary
Figure 2 and the comparison against the tCNNS which trained on whole existing data
is showed in Figure 4. From supplementary Figure 2, we see that tCNNS can achieve
Figure 4: The performance with different percentages of data used. The x-axis is the percentage
of data we use as training data from the total existing IC50 values (172114) in the database.
Since we will use 10% for validating and 10% for testing, the max x is 80%. The y-axis is
the performance of our model. The solid lines represent the result on total existing data, and
the dash lines represent the results where we just use the IC50 values below the max screening
concentration threshold(max conc), below which the data is more accurate. Since there are only
64, 440 values below max conc, so the dash lines end at around 64,440
172,114
∗ 80% = 30%
almost the same good result on max conc data only, which is faster because less data is
needed. There are some other properties of tCNNS that we can conclude from Figure
4. Firstly, it performs very well even with very limited training data. For example, even
trained on 1% of the existing IC50 values, R
2 can be almost 0.5 and Rp be around 0.7.
Secondly, and more importantly, tCNNS performed better with less and more accurate
data. We see that the dash lines (results on data below max conc) are always above the
solid lines (result on all data), and the final performance on max conc data is almost as
good as that on the total data, although the amount of data for the former is only 37%
of the later. To further compare the best performance on all data and max conc data
only, we repeated the experiments for 20 times to see the distribution of the results, and
show it in supplementary Figure 3.
There are three experimental results shown in Supplementary Figure ??, which are
the experiment on all data, on the data below max conc and on a random subset of
all data with the same size as those below max conc. Comparing the result on data
below max conc with the result on the random data with the same size, we see that the
1https://www.phosphosite.org/siteAction.action?id=3131
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performance of tCNNS is significantly better on data below max conc than on random
data with the same size, and this proved that tCNNS is able to utilize the accurate data.
Comparing the result on data below max conc with that on all data, we see that the
means of the towR2 are almost the same, and theRp on all data is only a little bit better
than that on the data below mac conc. Meanwhile, the variations ofR2 andRp on data
below max conc is a little bigger than those on all data. To conclude, the contribution
from low quality extrapolated data is limited, and they can only reduce variation and
improveRp a little bit.
Although the extrapolated data cannot enhance the accuracy of the model, they can
help to improve the scalability. The tCNNS model trained on all data performs well
when tested on data below max conc, which is natural because the later is a subset of
the former. However, the model trained on data belowmax conc performs poorly when
tested on all data. R2 drops to 0.33 and Rp drops to 0.6. Our explanation is that when
tCNNS is trained on all data, it learns some general pattern among all data. On the
contrary, when tCNNS is trained on data below max conc, it only learns the specific
patterns for this subset. So although the performance of tCNNS on all data and data
below max conc is similar, the paths they achieve the performance are different.
4.4 Blind Test For Drugs And Cell lines
In previous experiments, interaction pairs among drugs and cell lines are randomly
selected to be in training set, validation set, or testing set, which means that a specific
drug or a specific cell line can exist in training and testing at the same time, which
is a problem of drugs re-positioning. In the real world, drugs discovery is a more
challenging task in which we may not be able to train tCNNS on a specific drug or cell
line before testing on them. Instead, we may need to predict the performance of the
specific drug (or cell line) using tCNNS trained on other drugs(or other cell lines.) To
stimulate this condition, we design the blind test for drugs and cell lines respectively.
In the blind test for drugs, drugs are constrained from existing in training and testing
at the same time. We randomly select 10% (23/223) drugs and keep their related
textIC50 values for testing. For the remaining 90% drugs, we divide 90% of their
related IC50 values for training and 10% for validating.
In the blind test for cell lines, cell lines are prevented from existing in training set
and testing set at the same time. Similar to the case of drugs, we randomly select
10% (94/948) cell lines and keep their related textIC50 values for testing. For the
remaining 90% (904/948) cells, we used 90% of the related IC50 for training and 10%
for testing.
We repeat the blind test for drugs on all data and on the data below max conc
for 150 times respectively to see the distribution of the results. The same number of
experiments for the cell lines are also conducted. The results on all data are shown
in Figure 5. The results on data below max conc data are showed on supplementary
Figure 4 respectively.
From Figure 5 and supplementary Figure 4 we see that the performance of tCNNS
is comparably robust with the blind test for cell lines, but sensitive with the blind test
for drugs. Without the knowledge of drugs in training, the performance drops signifi-
cantly. Comparing the results in Figure 5 and supplementary Figure 4, we see that the
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Figure 5: Drug and cell blind test result on total data. Yellow color boxes represent the result of
cells blind, and blue color boxes for drugs blind. From up to down is the result for R2, Rp and
RMSR respectively. The red star is the result without controlling data distribution.
extrapolated data makes no contribution in this setting.
To conclude, it is very important to have the specific drug or cell line in the training
stage before we predict their performance. Experiments results support that even with
only one or two related IC50 value, the performancewill be significantly improved. For
example, NCI-H378 is a special cell line for lung cancer in GDSC that there are only
two IC50 values records for it. For other cell lines, all of them have at least 20 IC50
values. tCNNS can still make accurate predictions one of the IC50 values for textitNCI-
H378 if the other value is used during the training. Based our the results, the best drug
for NCI-H378 are Bortezomib, which has been explained previously [10, 17].
Meanwhile, tcNNS predicts another potential drug Docetaxel for them. The pre-
dicted IC50 value between Docetaxel and NCI-H378 is 0.03µg (third smallest for NCI-
H378), and the predicted IC50 between Docetaxel and NCI-H250 is 0.04µg (forth
smallest for NCI-H250). It is reported in [33] that APR-246 is a potential useful drug
on lung cancer because of its synergy with TP53 mutations in lung cells, and there is
a ”additive effects” between APR-246 and Docetaxel.
Comparing the results of the blind test for drugs and blind test for cell lines, we
guess the reason why the blind test for cell lines is slightly better is that there is more
common information shared among different cell lines and less among drugs. For
example, cell lines share similar genetic information, but drugs can be very diversified.
To reduce the information sharing among cells lines, we designed another experiment
in which cell lines from the same tissue cannot exist in training and testing at the same
time. The result is shown in Table 1.
In GDSC, the 948 cell lines belong to 13 tissue types and 49 sub-tissue types. We
choose to use the 13 tissue types instead of 49 sub-tissue types because it can increase
the distances and reduce the similarities among different tissues. Each time one tissue
type is selected as testing data. For the rest tissues, we mix them together and use 90%
for training and 10% data for validation. From Table 1, we can see that the performance
decrease differently for different tissues. For example, blood has the lowest R2 andRp
in all tissues, which indicates that blood is the most different tissue from other tissues.
From Table 1, we can also see that the result for validation is much better than testing,
which not only because we use validating as the stop criterion for our model, but also
because it shares more information with other tissues in the training stage.
The above results in the blind test give us some hint that with limited budgets, we
should carefully arrange the in vivo experiment to cover a wider range of drugs and
cells from different tissues to get better in silicon predicting power.
4.5 Cell Lines Features Impacts
In GDSC, the 735 features for cell lines after preprocessing belongs to 310 gene mu-
tation states, and 425 copy number variations. Since different laboratories may use
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different methods to extract the features for cell lines, in reality, it is not easy to have
the complete 735 features for all cells. More possibly, researchers may have smaller
and different features group for cell lines. It will be attractive if our tCNNS can have
good performance with fewer features for cell lines. In this part, we test tCNNS per-
formance with a different number of features for cell lines. All the results in this part
are shown in Figure 6.
Figure 6: Sensitivity to the number of features. The x-axis is the number of mutation states used
for cells in the experiments, and the y-axis is the performance we achieved.
4.6 Biological Meaning v.s Statistical Meaning
tCNNS takes the one-hot representation of the SMILES format as the features for
drugs. Initially, in the one-hot representation of the SMILES format, each row repre-
sents a symbol, and each column represents a position in the SMILES format, which is
left aligned. For human researchers, the SMILES format is a well-defined concept with
biological meaning. However, we think tCNNS may lack the ability to comprehend the
biological meaning of the SMILES format and it instead relies on the statistical pattern
inside the data. To verify this hypothesis, we modify the one-hot representation of the
SMILES format in three ways. Firstly, we randomly shuffle the order of the symbols,
which equals shuffling the rows in the one-hot representation. Secondly, we cut the
SMILES format into two pieces and switch their positions, which equals shifting the
columns in the one-hot representation. Thirdly, we shuffle the positions in the SMILES
format, which equals shuffling the columns in the one-hot representation. In the last
two ways of the modification, the biological meaning of SMILES is corrupted. We
repeat the experiments in the three settings for 10 times respectively and compare the
results to the result using the SMILES format without any modification as the bench-
mark. The comparison is shown in supplementary Figure 5.
Since the computation of different channels (the rows in the one-hot representation
of SMILES format) are independent of each other in the convolution neural network,
we think the result should keep the same in the first modification with the benchmark.
In the second modification, shifting the SMILES will only change the three column in
the one-hot representation: the two ends columns and the column where we start the
shifting. Meanwhile, other columns keep the same. Thus, we also think that the result
in the secondmodification should keep the samewith the benchmark. The experimental
results do support our predictions in the first two modifications. What surprised us is
that the performance also keeps similar in the third modification. We used to think
that shuffling the positions in the SMILES format will deteriorate the result because
it corrupted the structure of the SMILES format. This stability means that tCNNS
actually does not capture the biological meaning of the SMILES format for drugs, and
it relies on the statistical patterns inside the SMILES format, cell line features, and the
IC50 values.
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4.7 Eliminating Outlier
In the last column in supplementary Figure 5, we compared the results of tCNNS with
the results of benchmark [30]. As GDSC has changed in recent years, we can not use
the same data as [30]. In the experiment, we follow the method introduced in [30] and
apply it to current data. We use PaDEL(version 2.1.1) to extract 778 features for each
drug. For cell lines, we use the same 735 features, instead of the 157 features in the old
version of GDSC used in [30].
Figure 7: Visualization of drugs and cells in the high-dim space. a) Drugs in PaDEL space(778
dims), b) Drugs in CNN space(420 dims), c) cells in mutation space(735 dims), d) cells in CNN
space(1680 dims)
To compare the features extracted using PaDEL and features extracted from the
SMILES format using CNN, we visualize the distribution of the drugs in different
feature spaces to check the difference. When drawing the distribution of drugs using
CNN, we use the output of the last layer of CNN tranche for drugs. The reason is that
in deep neural network, the fully connected layer is responsible for regression analysis,
and CNN is for extracting the high-level features from the drugs features. The input
data for the fully connected network is the output of CNN tranche. So drawing the
distribution of drugs using the output of the last layer in CNN is more reasonable.
We also compared the distribution of cell lines in features space of GDSC, and in
the output space of the last layer in CNN respectively. The visualization tool we used
is t-SNE[28], which is widely used to visualize high dimensional data in deep learning.
The visualization results are shown in Figure 7. We can see that CNN can distribute
the drugs and cell lines more uniformly than features using PaDEL and features of
GDSC. For drugs, we see that there are seven outliers in the PaDEL features space.
These seven outliers are the only seven drugs that are composed of multiple parts. We
show the structure of those drugs in supplementary Figure 6.
5 Conclusion
In this paper, we came up with a model tCNNS for phenotypic screening between
cancer cell lines and anti-cancer drugs. tCNN is tested on a new version of GDSC
with more data compared to previous works. It achieved a much better coefficient
of determinant and Pearson correlation than previous works and made predictions for
missing values in GDSC with trustful evidence. tCNNS can also converge with a very
small set of training data and fewer features for cancer cell lines, which is economically
efficient. tCNNS took SMILES as the input data for drugs, and this eliminated the
outlier problem in previous works in which drugs fingerprint are used as the features.
tCNNS performs better in drugs repurposing than drug discovery, this may be a future
research topic.
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Tissue name
Data
Amount
R2 Rp RMSR
aero digestive 13806 0.703 0.843 0.0375
tract (0.826) (0.916) (0.0280)
blood 31119 0.500 0.724 0.0449
(0.833) (0.917) (0.0276)
bone 6826 0.659 0.813 0.0405
(0.825) (0.915) (0.0283)
breast 9277 0.657 0.811 0.0383
(0.829) (0.919) (0.0281)
digestive 17200 0.667 0.817 0.0384
system (0.830) (0.918) (0.0282)
kidney 5199 0.669 0.819 0.0386
(0.822) (0.914) (0.0286)
lung 34086 0.614 0.784 0.0371
(0.827) (0.919) (0.0285)
nervous 15763 0.702 0.839 0.0364
system (0.830) (0.918) (0.0280)
pancreas 5358 0.703 0.840 0.0370
(0.820) (0.913) (0.0287)
skin 10488 0.676 0.824 0.0394
(0.827) (0.917) (0.0281)
soft tissue 3165 0.712 0.853 0.0384
(0.821) (0.914) (0.0284)
thyroid 2715 0.672 0.822 0.0410
(0.833) (0.918) (0.0277)
urogenital 17112 0.715 0.849 0.0363
system (0.825) (0.914) (0.0282)
Table 1: Tissue-Specific Test. The first column is the 13 tissue names and we range them in
alphabetical order. The second column is the ground true IC50 values for each tissue. The last
two columns are the R2 and Rp our model achieved by training using all the other tissue data.
The number in the bracket is the result for the validation set.
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